Histogenics Corp is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The company's first product candidate, NeoCart, is a tissue implant that utilizes various aspects of regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. Histogenics operates in two geographic regions: The United States (Massachusetts) and Israel (Tel Aviv). Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based therapies, gene therapy, small molecules and biologics, stem cells and biobanking.